Reduce the necessary number of capsules! Stax mAx Clarification Platform
Stax mAx Clarification Platform
Removal and clarification of monoclonal antibody (mAb) producing cells with stable and high processing capability that is less affected by cell density and viable cell rate.
The Stax(TM) mAx clarification platform is a robust, safe, and economical clarification solution that minimizes the use of centrifuges and additives. It consists of a four-layer filter system that combines a coarse clarification grade two-layer depth filter with a precise clarification grade two-layer depth filter. This optimized combination provides stable and high processing capacity that is less affected by cell density and viable cell rates. For culture media with a cell density of 35x10^6 cells/mL and turbidity of approximately 3,000 NTU, the required filtration area is reduced by 25-50% compared to conventional products. It achieves a scalable and simple clarification process that contributes to cost reduction and reduced installation area. ■ Do not want to use a centrifuge ■ Do not want to use additives ■ Want stable processing capacity despite variations in cell density and viable cell rates ■ Struggling with the high usage of depth filters This is ideal for those who have these needs. We are accepting trials using your cell culture media at any time. Please contact us for more details.
Inquire About This Product
Related Videos
basic information
■High processing capacity and clarity are achieved through coarse primary clarification filtration grade (Stage 1: PDP8) and precise secondary clarification filtration grade (Stage 2: PDE2). ■Filtration area can be seamlessly scaled up from 22 square centimeters to 1.0 square meter. ■Depth filter: cellulose.
Price range
Delivery Time
Applications/Examples of results
■ Cell removal and clarification ■ Cell density up to a maximum of 35x10^6 cells/mL, turbidity up to approximately 3000 NTU
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
